Genedata Selector for NGS-Based Gene Therapy Characterization: NGS as Multi-Attribute Method to Support AAV Gene Therapy Production
In this webinar, Qiu Ruan, Ph.D., Scientific Account Manager at Genedata presents how Genedata Selector® supports AAV gene therapy production and critical quality attribute assessment (CQA) using NGS, the Multi-Attribute Method.
Qiu discusses the following critical aspects to ensure the production of safe viral-based gene therapies:
- Monitoring sequence integrity of the vector genome to ensure it has not accumulated any mutations during production,
- Checking for any plasmid contamination within the capsid, such as packaging plasmids, helper plasmids, or host cell sequence within the final product
- Checking for the presence of adventitious agents, such as unexpected viruses in the product
The outcome of this analysis example is a clear overview of the QC results across these three different NGS-based assays.
During her talk, Qiu demonstrates how our platform eliminates the complexity of insight generation from NGS data by automating data processing and analysis while delivering relevant results to stakeholders for accelerated decision-making through clear, actionable go/no-go signals.
This talk was given as part of our regular Open Forums on NGS-based QC for AAV Vectors.
Who should watch?
Biopharma and biotech professionals looking to advance analytical development, biosafety, and QC by embracing digitalization and innovative enterprise data analysis systems.